Baseline characteristics of patients with systemic sclerosis with vs. without clinically meaningful %-predicted FVC worsening.
| Full Analytic Cohort, n = 138 | Radiographic ILD Present, n = 100 | |||||
|---|---|---|---|---|---|---|
| No FVC Decline, n = 89 | FVC Decline ≥ 5, n = 49 | P | No FVC Decline, n = 61 | FVC Decline ≥ 5, n = 39 | P | |
| Age at time of HRCT, yrs | 49.2 (± 11.9) | 51.7 (± 9.4) | 0.18 | 48.6 (± 12.4) | 51.0 (± 10.1) | 0.28 |
| Sex, women | 78 (87.6) | 38 (77.6) | 0.19 | 52 (85.2) | 30 (76.9) | 0.43 |
| Race, White | 67 (75.3) | 37 (75.5) | > 0.99 | 42 (68.9) | 28 (71.8) | 0.93 |
| Smoker, current or former | 32 (36.0) | 20 (40.8) | 0.70 | 20 (32.8) | 17 (43.6) | 0.38 |
| GI symptomsa, present | 66 (74.2) | 36 (73.5) | > 0.99 | 44 (72.1) | 30 (76.9) | 0.77 |
| Pulmonary symptomsa, present | 53 (59.6) | 30 (61.2) | 0.99 | 38 (62.3) | 28 (71.8) | 0.45 |
| PPI use, current | 53 (59.6) | 28 (57.1) | 0.93 | 36 (59.0) | 24 (61.5) | 0.97 |
| dcSSc subtype | 42 (47.2) | 22 (44.9) | 0.94 | 36 (59.0) | 18 (46.2) | 0.29 |
| SSc disease durationb, yrs | 5.6 (± 7.5) | 5.8 (± 8.1) | 0.89 | 4.1 (± 5.1) | 5.5 (± 6.9) | 0.27 |
| Scl-70, positive | 25 (28.1) | 25 (51.0) | 0.01 | 24 (39.3) | 24 (61.5) | 0.05 |
| Anticentromere, positive | 17 (19.1) | 7 (14.3) | 0.63 | 4 (6.6) | 2 (5.1) | > 0.99 |
| Anti-RNAP3, positive | 26 (29.9) | 8 (16.7) | 0.14 | 19 (31.7) | 5 (12.8) | 0.06 |
| ESR | 24 (± 25.1) | 23 (± 17.8) | 0.82 | 20 (± 18.1) | 25 (± 19.2) | 0.24 |
| mRSS | 11.9 (± 9.7) | 10.5 (± 7.5) | 0.34 | 13.8 (± 10.1) | 10.9 (± 7.8) | 0.12 |
| Medications, any use | 41 (46.1) | 23 (46.9) | > 0.99 | 32 (52.5) | 20 (51.3) | > 0.99 |
| Cyclophosphamide | 4 (4.5) | 2 (4.1) | > 0.99 | 4 (6.6) | 2 (5.1) | > 0.99 |
| Mycophenolate mofetil | 18 (20.2) | 13 (26.5) | 0.53 | 15 (24.6) | 12 (30.8) | 0.65 |
| Prednisone | 24 (27.0) | 11 (22.4) | 0.71 | 18 (29.5) | 9 (23.1) | 0.63 |
| PAH present among those with RHC (N = 56) | 8 (26.7) | 11 (42.3) | 0.34 | 6 (28.6) | 11 (47.8) | 0.32 |
| Radiographic ILD, present | 61 (68.5) | 39 (79.6) | 0.23 | 61 (100.0) | 39 (100.0) | NA |
| FVC% predicted, baseline | 77 (± 16.8) | 79 (± 16.8) | 0.71 | 74 (± 17.9) | 75 (± 16.6) | 0.79 |
| DLCO% predicted, baseline | 60 (± 19.6) | 59 (± 21.8) | 0.74 | 59 (± 20.2) | 54 (± 19.3) | 0.20 |
| Digital ulcers, present | 38 (42.7) | 14 (28.6) | 0.15 | 30 (49.2) | 10 (25.6) | 0.03 |
| WED, mm | 17.2 (± 7.9) | 18.3 (± 8.6) | 0.43 | 18.6 (± 7.6) | 18.6 (± 8.3) | 0.99 |
Values are expressed as mean (SD) or n (%).
↵aPulmonary and GI symptoms defined as positive pulmonary and/or GI review of systems in an outpatient rheumatology clinic note within 1 year of HRCT date.
↵bSSc disease duration defined as the interval between first non-Raynaud SSc symptom and baseline HRCT date. dcSSc: diffuse cutaneous systemic sclerosis; DLCO: diffusing capacity for carbon monoxide (adjusted for hemoglobin); ESR: erythrocyte sedimentation rate; FVC: forced vital capacity; GI: gastrointestinal; HRCT: high-resolution computed tomography of the chest; ILD: interstitial lung disease; mRSS: modified Rodnan skin score; NA: not applicable; PAH: pulmonary arterial hypertension; PPI: proton pump inhibitor; RHC: right heart catheterization; RNAP3: RNA polymerase III; Scl-70: antitopoisomerase I; SSc: systemic sclerosis; WED: widest esophageal diameter.